INNOVATE's MediBeacon receives CE Mark for TGFR Monitor and Reusable Sensor under EU MDR

INNOVATE Corp.

MediBeacon (equity method investment of INNOVATE) obtained EU CE Mark under MDR for TGFR Monitor and Reusable Sensor.
Devices are Class IIa; TGFR System enables transdermal assessment of kidney function (tGFR).
CE Mark allows potential use in European clinical trials; Lumitrace injection approved in U.S. and China.
Dr. Lui Forni plans to include transdermal GFR in his clinical research in Europe later this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.